# A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

> **NCT01870999** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** aripiprazole IM depot
- **DRUG:** aripiprazole tablets

## Key facts

- **NCT ID:** NCT01870999
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870999, "A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01870999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*